STELARA® Dosing and Administration

STELARA®, available as 45 mg and 90 mg, is a subcutaneous injection intended for use under the guidance and supervision of a physician with patients who will be closely monitored and have regular follow-up. Patients may self-inject with STELARA® after physician approval and proper training. Patients should be instructed to follow the directions provided in the Medication Guide.1

For patients weighing

≤220 lbs
The recommended dose is…

45 mg dosed subcutaneously initially and 4 weeks later, followed by 45 mg every 12 weeks

For patients weighing

>220 lbs
The recommended dose is…

90 mg dosed subcutaneously initially and 4 weeks later, followed by 90 mg every 12 weeks*

 

*In patients weighing >220 lbs, 45 mg was also shown to be efficacious. However, 90 mg resulted in greater efficacy in these patients.1

Uncover a Dosing Schedule With the Fewest Doses Per Year1-6

Dosing every 12 weeks after 2 starter doses at Weeks 0 and 41

2 injections
STELARA®

(ustekinumab)

Once every 12 weeks (after 2 starter doses at Weeks 0 and 4)

7 injections
Humira®

(adalimumab)

Once every other week (starting 1 week after initial dose of 1 80-mg injection)

24 injections
Enbrel®

(etanercept)

Once every week (after twice-weekly doses for the first 3 months)*

14 injections
Cosentyx®

(secukinumab)

Once every 4 weeks (after once-weekly dosing for the first 5 doses; 2 injections per dose)

8 injections
Taltz®

(ixekizumab)

Once every 4 weeks (after 2 injections given at Week 0, followed by 1 injection every 2 weeks for the next 6 doses through Week 12)

6 injections
STELARA®

(ustekinumab)

Once every 12 weeks (after 2 starter doses at Weeks 0 and 4)

27 injections
Humira®

(adalimumab)

Once every other week (starting 1 week after initial dose of 1 80-mg injection)

64 injections
Enbrel®

(etanercept)

Once every week (after twice-weekly doses for the first 3 months)3

34 injections
Cosentyx®

(secukinumab)

Once every 4 weeks (after once-weekly dosing for the first 5 doses; 2 injections per dose)

18 injections
Taltz®

(ixekizumab)

Once every 4 weeks (after 2 injections given at Week 0, followed by 1 injection every 2 weeks for the next 6 doses through Week 12)

14 injections
STELARA®

(ustekinumab)

Once every 12 weeks (after 2 starter doses at Weeks 0 and 4)

79 injections
Humira®

(adalimumab)

Once every other week (starting 1 week after initial dose of 1 80-mg injection)

168 injections
Enbrel®

(etanercept)

Once every week (after twice-weekly doses for the first 3 months)*

86 injections
Cosentyx®

(secukinumab)

Once every 4 weeks (after once-weekly dosing for the first 5 doses; 2 injections per dose)

44 injections
Taltz®

(ixekizumab)

Once every 4 weeks (after 2 injections given at Week 0, followed by 1 injection every 2 weeks for the next 6 doses through Week 12)

2189 injections
Otezla®

Tablets for oral use Five-day titration (one dose on Day 1, twice-daily dosing on Days 2 to 5; followed by twice-daily maintenance dosing)

23 injections
STELARA®

(ustekinumab)

Once every 12 weeks (after 2 starter doses at Weeks 0 and 4)

131 injections
Humira®

(adalimumab)

Once every other week (starting 1 week after initial dose of 1 80-mg injection)

272 injections
Enbrel®

(etanercept)

Once every week (after twice-weekly doses for the first 3 months)*

138 injections
Cosentyx®

(secukinumab)

Once every 4 weeks (after once-weekly dosing for the first 5 doses; 2 injections per dose)

70 injections
Taltz®

(ixekizumab)

Once every 4 weeks (after 2 injections given at Week 0, followed by 1 injection every 2 weeks for the next 6 doses through Week 12)

3649 injections
Otezla®

(apremilast)

Tablets for oral use Five-day titration (one dose on Day 1, twice-daily dosing on Days 2 to 5; followed by twice-daily maintenance dosing)

This presentation is not intended to compare the relative safety or efficacy of these treatments.
Please refer to the Prescribing Information of each agent for dosage and administration.

Indicated trademarks are registered trademarks of their respective owners.

 

In addition to the 50-mg twice-weekly recommended starting dose, starting doses of 25 mg or 50 mg per week were shown to be efficacious. The proportion of responders was related to Enbrel® dosage.3

Based on the recommended 300-mg dose. 150 mg may be acceptable for some patients.4

STELARA® is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Humira® is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Humira® should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.2

Enbrel® is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.3

Cosentyx® is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.4

Taltz® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.5

Otezla® is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.6

 

 

References: 1. STELARA® (ustekinumab) [package insert]. Horsham, PA: Janssen Biotech, Inc. 2. Humira (adalimumab) [package insert]. North Chicago, IL: AbbVie Inc. 3. Enbrel® (etanercept) [package insert]. Thousand Oaks, CA: Immunex Corporation. 4. Cosentyx (secukinumab) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. 5. Taltz (ixekizumab) [package insert]. Indianapolis, IN: Eli Lilly and Company. 6. Otezla (apremilast) [package insert]. Summit, NJ: Celgene Corporation.